The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -14,259 | -36,514 |
| Depreciation and amortization | 19 | 240 |
| Share-based compensation | 1,238 | 5,305 |
| Amortization of premium and discount on marketable securities | -375 | -102 |
| Rou asset amortization | 352 | 491 |
| Prepaid expenses and other current assets | -4,021 | -783 |
| Accounts payable | 500 | 346 |
| Accrued expenses | -2,308 | 4,705 |
| Operating lease liability | -37 | -294 |
| Net cash used in operating activities | -10,849 | -25,040 |
| Purchase of property and equipment | 7 | 18 |
| Purchases of marketable securities | 109,077 | 58,005 |
| Proceeds from sale or maturities of marketable securities | 13,928 | 63,251 |
| Net cash (used in) provided by investing activities | -95,156 | 5,228 |
| Proceeds from issuance of common stock and warrants | 137,999 | 0 |
| Issuance costs from issuance of common stock | 8,638 | 0 |
| Taxes paid related to net shares settlement of rsus | 0 | 815 |
| Net cash provided by financing activities | 129,361 | -815 |
| Net change in cash, cash equivalents and restricted cash | 23,356 | -20,627 |
| Cash and cash equivalents at beginning of period | 44,051 | - |
| Cash and cash equivalents at end of period | 46,780 | - |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)